Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumab
Rheumatol (Oxford), 2025 DOI: 10.1093/rheumatology/keaf215. Epub ahead of print
The study analysed data from 796 SLE patients from the phase III BLISS-SC trial, incorporating B cell subset distribution and antibody status to define endotypes. The aim was to explore whether immunological profiling could predict clinical response to belimumab, providing a basis for precision medicine in SLE treatment.